Managing PD-L1-Positive NSCLC in the Long-Term

Anne Chiang, MD, PhD, associate professor of medicine in the Section of Medical Oncology, Yale School of Medicine, discusses the takeaways from her presentation given at the 18th Annual New York Lung Cancers Symposium.

According to Chiang, experts should be on the lookout for results from the INSIGNA trial (NCT03793179) as the study may offer significant insights into PD-L1-positive disease and its correlation with treatment response for patients with lung cancer. Due to advancements in therapies, patients with PD-L1-positive disease are now experiencing longer survival and improved quality-of-life. Based on this, Chiang highlights the importance of clinical trial participation.

In addition, Chiang discusses the importance of understanding the full implications of biomarkers in this space as well as the continued need to develop effective sequencing strategies.

Transcription:

0:09 | I think my main message is, stay tuned for the results of the INSIGNA trial. I think that's really going to inform our choices, and help us to understand more of PD-L1-positive disease and what it correlates with, if there's a signature that correlates with response for our patients.

0:29 | I think my second message is that these patients are living longer and doing better. So get those patients on clinical trials. None of these patients if they went with their standard first-line therapy at the time, which was with platinum-based chemotherapy, if they hadn't gone into this trial, these trials first-line, we wouldn't have these kinds of options for our patients.

0:54 | My third message would be that I think that we need to understand better what these biomarkers mean. What PD-L1-low means, [and] is this a special population? For example, those 1 to 49 folks that need more than monotherapy, such as the addition of chemotherapy, such as the addition of radiation or a different novel agent or another combination immunotherapy agent. So a lot of outstanding questions, and we'll learn more about sequencing. I think that as our patients live longer, it's going to be really important to have not only great options [in the] first-line, but then continued options for them if they progress.